Skip to Content

'
Nitin Jain, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2003 All India Institute of Medical Sciences (AIIMS), New Delhi, India, MBBS, Bachelor of Medicine and Bachelor of Surgery (MBBS), Medicine

Postgraduate Training

7/2009-6/2012 Clinical Fellowship, Hematology-Oncology, University of Chicago Medical Center, Chicago, IL, Dr. Ezra Cohen
7/2008-6/2009 Clinical Fellowship, Leukemia, Memorial Sloan-Kettering Cancer Center, New York, NY, Dr. Mark Weiss
7/2007-6/2008 Clinical Fellowship, Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Jorge Cortes
7/2004-6/2007 Clinical Residency, Internal Medicine, Medical College of Wisconsin, Milwaukee, WI, Dr. Michael Frank
1/2003-10/2003 House Officer, All India Institute of Medical Sciences, New Delhi, India
1/2002-12/2002 Clinical Internship, All India Institute of Medical Sciences, New Delhi, India

Board Certifications

10/2012 Hematology
10/2012 Medical Oncology
8/2007 Internal Medicine

Honors and Awards

2008 Merit Award, American Society of Clinical Oncology (ASCO), ASCO
2006 Member of Winning Team, American College of Physicians (Wisconsin Chapter) Doctors' Dilemma Medical Quiz Competition, ACP
1999 AIIMS Institute Prize for Best Undergraduate in Microbiology, AIIMS
1999 Sardari Lal Kalra Gold Medal in Microbiology, AIIMS
1997 First Rank in the country (India) for Medical School Entrance Examination, AIIMS
1997 National Merit Scholarship, Government of India

Selected Publications

Peer-Reviewed Original Research Articles

1. Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN, Jain N, Luthra R, Jeffrey Medeiros L, Khoury JD. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol 88(12):1055-61, 12/2013. e-Pub 9/30/2013. PMID: 23940084.
2. Jain N, Khoury JD, Pemmaraju N, Kollipara P, Kantarjian H, Verstovsek S. Imatinib Therapy in a Patient with Suspected Chronic Neutrophilic Leukemia and FIP1L1-PDGFRA Rearrangement. Blood 122(19):3387-8, 11/7/2013. PMID: 24203930.
3. Jain N, O'Brien S. The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment. Expert Rev Hematol 6(5):575-86, 10/2013. e-Pub 10/2/2013. PMID: 24083594.
4. Jain N, Liu H, Artz AS, Anastasi J, Odenike O, Godley LA, Joseph L, Marino S, Kline J, Nguyen V, Schouten V, Kunnavakkam R, Larson RA, Stock W, Ulaszek J, Savage PA, Wickrema A, van Besien K. Immune Reconstitution after Combined Haploidentical and Umbilical Cord Blood Transplantation. Leuk Lymphoma 54(6):1242-9, 6/2013. e-Pub 3/1/2013. PMID: 23088744.
5. Hossain N, Jain N, Steinmetz J, McConville J, Anastasi J. A 32-year-old man with persistend cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia. Chest 142(6):1680-3, 12/2012.
6. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 115(6):1131-6, 2/11/2010. e-Pub 12/11/2009. PMID: 20008298.
7. Sever M, Kantarjian H, Pierce S, Jain N, Estrov Z, Cortes J, Verstovsek S. Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation. Int J Hematol 90(4):522-5, 11/2009. e-Pub 8/2009. PMID: 19728024.
8. Jain N, Wierda W, Ferrajoli A, Wong F, Lerner S, Keating M, O'Brien S. A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer 115(19):4533-9, 10/2009. PMID: 19637351.
9. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 115(17):3924-34, 9/2009. PMID: 19536894.
10. Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian H. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer 115(14):3217-21, 7/2009. PMID: 19441109.
11. Jain N, Cortes J, Quintás-Cardama A, Manshouri T, Luthra R, Garcia-Manero G, Kantarjian H, Verstovsek S. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status. Leuk Res 33(6):837-9, 6/2009. e-Pub 11/2008. PMID: 19013640.
12. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 113(21):5058-63, 5/2009. e-Pub 3/2009. PMID: 19282457.
13. Verma D, Kantarjian H, Jain N, Cortes J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk Lymphoma 49(7):1399-402, 7/2008. PMID: 18452066.
14. Jain N, Hubbard J, Vega F, Vidal G, Garcia-Manero G, Borthakur G. Spontaneous Remission of Acute Myeloid Leukemia: report of three patients and review of literature. Clinical Leukemia 2(1):64-67, 2/2008.
15. Jain N, Kantarjian H, Ault P, Cortes J. Scrotal edema associated with the use of dasatinib in patients with chronic myeloid leukemia. Clinical Leukemia 1(6):357-58, 12/2007.
16. Jain N, Fisk D, Sotir M, Kehl KS. West Nile encephalitis, status epilepticus and West Nile pneumonia in a renal transplant patient. Transplant International 20(9):800-3, 9/2007. e-Pub 7/2007. PMID: 17630998.
17. Jain N, Patel D, Pfeifer KJ. An unusual case of vertebral osteomyelitis in a young healthy adult. Wisconsin Medical Journal 106(3):152-54, 5/2007.
18. Prasad K, Singhal T, Jain N, Gupta PK. Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis, 1/2004.

Invited Articles

1. Jain N, O'Brien S. The frontline treatment of CML in the chronic phase: current clinical decisions and future prospects for treatment. Expert Review of Hematology 6(5):575-86, 10/2013.
2. Jain N, O'Brien S. Ibrutinib (PCI-32765) in Chronic Lymphocytic Leukemia. Hematol Oncol Clin North Am 27(4):851-60, 8/2013. PMID: 23915749.
Other Articles
1. Van Besien K, Liu H, Jain N, Stock W, Artz A. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biology of Blood and Marrow Transplantation 19(5):682-91, 5/2013.
2. Van Besien K, Liu H, Jain N, Stock W, Artz A. Umbilical Cord Blood Transplantation Supported by Third-Party Donor Cells: Rationale, Results, and Applications. Biol Blood Marrow Transplant 19(5):682-91, 5/2013. e-Pub 11/8/2012. PMCID: PMC3618995.
3. Jain N, O'Brien S. Chronic lymphocytic leukemia with deletion 17p: emerging treatment options. Oncology (Williston Park) 11(11):1067-70, 11/2012. PMID: 23330347.
4. Jain N, van Besien K. Chronic Myelogenous Leukemia. Elsevier's First Consult online, 1/2012.
5. Quintas-Cardama A, Jain N, Verstovsek S. Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis. Cancer 117(24):5439-49, 12/2011. e-Pub 6/2011. PMID: 21692073.
6. Jain N, van Besien K. Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin North Am 25(5):1025-48, vi, 10/2011. PMCID: PMC3246008.
7. Jain N, Odenike O. The Emerging Role of the Histone deactylase inhibitor Romidepsin in Hematologic Malignancies. Expert Opinion on Pharmacotherapy 11(18):3073-84, 12/2010.
8. Garcia JS, Jain N, Godley LA. An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. OncoTargets and Therapy 24(3):1-13, 6/2010.
9. Jain N, Lamanna N. Incorporating Prognostic Information into Treatment Decisions in CLL. Current Oncology Reports 11(5):353-9, 9/2009.
10. Jain N, Rossi A, Garcia-Manero G. Epigenetic therapy of leukemia: An update. The International Journal of Biochemistry and Cell Biology 41(1):72-80, 1/2009.
11. Jain N, Verstovsek S. Systemic Mastocytosis. Drugs of the Future 33(2):187-92, 2008.

Abstracts

1. Faderl S, Jain N, O'Brien SM, Thomas DA, Ravandi F, Jabbour E, Pierce S, Kantarjian HM. Inotuzumab ozogamicin (CMC-544) compared to chemotherapy in patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): A retrospective comparison. ASCO MEETING ABSTRACTS:7095, 6/2013.
2. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia (CLL) with 17p deletion (del17p). ASCO MEETING ABSTRACTS:7102, 6/2013.
3. Jain N, O'Brien SM, Thomas DA, Jabbour E, Faderl S, York S, Kantarjian HM. Phase I/II study of the combination of inotuzumab ozogamicin (CMC-544) with low-intensity chemotherapy in patients (pts) with acute lymphoblastic leukemia (ALL). ASCO MEETING ABSTRACTS:7092, 6/2013.
4. Takahashi K, Kantarjian HM, Ghanem H, Ravandi F, Cortes JE, Kadia TM, O'Brien S, Pierce SA, Jain N, Garcia-Manero G, Jabbour EJ. Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure, 12/2012.
5. van Besien K, Jain N, Schouten V, Liu H, Ulaszek J, Wickrema A, Artz AS. Immune-reconstitution after combined haploidentical and umbilical cord blood transplantation, 6/2012.
6. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum M, Erba HP, Green M, Poire X, Koval G, Shannon K, Atallah E, Dy PA, Smith SE, Doyle LA, Larson RA, Stock W, Odenike O. Phase II Study of the Oral MEK Inhibitor Selumetinib (AZD6244) in advanced Acute Myeloid Leukemia (AML), 6/2012.
7. Jain N, Kantarjian HM, Garcia-Manero G, Borthakur G, Ebarb T, Cortes JE. Synthetic tumor-specific breakpoint peptide vaccine in patients (pts) with chronic myeloid leukemia (CML) and minimal residual disease: A phase II trial, 2008.
8. Jain N, Mattiuzzi GN, Cortes J, Cassat J, Garcia-Manero G, Ravandi-Kashani F, Pierce S, Borthakur G, O'Brien S, Kantarjian HM. Benefit of anti-infectious prophylaxis in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome receiving frontline targeted therapy, 11/2007.
9. Jain N, Kantarjian HM, Fava C, Thomas D, Burger JA, Borthakur G, Pate O, Cortes J. Imatinib dose can be safely reduced after complete cytogenetic response in patients with chronic myeloid leukemia in early chronic phase treated with high-dose imatinib, 11/2007.
10. Borthakur G, Jain N, Kantarjian H, Lin E, Ravandi F, Pierce S, Estey E. Survival is poorer in patients with secondary core binding factor acute myelogenous leukemia compared with de novo core binding factor leukemia, 11/2007.
11. Jain N, Malhotra S, Girotra S, Nanchal R, Khan RA. Hyperammonemia: Think beyond the liver, 12/2006.
12. Jain N, Pasquini M, Paul M, Hari P. Autologous stem cell transplantation (ASCT) in AL amyloidosis: Feasibility outside national amyloidosis referral centers and proposal for simpler pre-transplant staging, 6/2006.
13. Jain N, Patel D, Pfeifer KJ. An unusual case of vertebral osteomyelitis in a young healthy adult, 4/2006.
14. Jain N, Fisk D, Sotir M. West Nile encephalitis with status epilepticus and West Nile pneumonia in a solid organ transplant recipient: Think before you test, 2006.

Book Chapters

1. Jain N, Gurbuxani S, Rhee C, Stock W. Acute Lymphocytic Leukemia in Adults. In: Hematology: Basic Principles and Practice (Hoffman's), 6th Edition. Churchill Livingstone, 2012.
2. Jain N, Verstovsek S. Philadelphia-chromosome negative myeloproliferative disorders. In: The MD Anderson Manual of Medical Oncology, 2nd Edition. McGraw-Hill Professional, 2011.

Last updated: 6/6/2014